The relative contribution of <scp>NSAIDs</scp> and <scp><i>H</i></scp><i>elicobacter pylori</i> to the aetiology of endoscopically‐diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the <scp>UK</scp> between 2005 and 2010

Musumba, Crispin; Jorgensen, Andrea; Sutton, Laura; Eker, Diane Van; Moorcroft, Jay; Hopkins, Maeve K.; Pritchard, D. Mark; Pirmohamed, Munir

doi:10.1111/j.1365-2036.2012.05118.x

Cited by 55 publications

(36 citation statements)

References 42 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies from the 1980s and 1990s, showed the prevalence of H. pylori infection was 90% in duodenal ulcer and 70% in the gastric ulcer (10) . The prevalence of H. pylori infection has been decreasing steadily over the last decades, especially in industrialized countries while the prevalence of peptic ulcer associated with the use of NSAID apparently is increasing (9,14,15) . The prevalence of peptic ulcer not related to H. pylori nor NSAID -idiopathic PUD -is increasing according to some studies (4,9,24) .…”

Section: Introductionmentioning

confidence: 99%

“…In North America, it has been reported as 20% to 40%, in Southern Europe as 4.1% to 8% and the Northern Europe as 10% to 15%. Asia and undeveloped countries have low prevalence of idiopathic peptic ulcer (15) . Recent data available from Brazil still point out for high prevalence of H. pylori infection (19,20,25) and there are mismatched reports on duodenal ulcer prevalence (12,21) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Peptic Ulcer Frequency Differences Related to H. Pylori or Aines

Carli

Pires

Rohde

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Peptic ulcer etiology has been changing because of H. pylori decline. Objective -To estimate peptic ulcer prevalence in 10 years-interval and compare the association with H. pylori and use of non-steroidal anti-inflammatory drugs. Non-steroidal anti-inflammatory drugs use was 3.5% in A and 13.3% in B. Neither condition occurred in 10.4% and 20.5% in A and B respectively. Comparing both periods, we observed reduction of peptic ulcer associated to H. pylori (P=0.000), increase of peptic ulcer related to non-steroidal anti-inflammatory drugs (P=0.000) and idiopathic peptic ulcer (P=0.002). The concurrent association of H. pylori and non-steroidal anti-inflammatory drugs was also higher in B (P=0.002). Rates of gastric ulcer were higher and duodenal ulcer lower in the second period. Conclusions -After 10 years, the prevalence of peptic ulcer decreased, as well as ulcers related to H. pylori whereas ulcers associated to non-steroidal anti-inflammatory drugs increased.There was an inversion in the pattern of gastric and duodenal ulcer and a rise of idiopathic peptic ulcer. HEADINGS -Peptic ulcer. Helicobacter pylori. Non-steroidal anti-inflammatory agents. Stomach ulcer. Duodenal ulcer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Peptic Ulcer Frequency Differences Related to H. Pylori or Aines

Carli

Pires

Rohde

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…In Western countries, the use of NSAIDs is reportedly the most important cause of upper gastrointestinal (GI) injury (Lassen et al 2006;Cai et al 2009;Musumba et al 2012). A similar trend has become apparent in Japan, where the prevalence of drug-induced peptic ulcers should soon surpass that of conventional Helicobacter pylori-infected peptic ulcers (Ootani et al 2006).…”

Section: Introductionmentioning

confidence: 86%

Increased Gastric Mucus Secretion Alleviates Non-Steroidal Anti-Inflammatory Drug-Induced Abdominal Pain

Iwabuchi

Iijima

Ara

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) can cause dyspeptic symptoms, including abdominal pain. Gastric mucus is important as the first line of defense against luminal irritants. In the present study, we investigated whether gastric mucus secretion could influence the severity of gastric mucosal injuries or NSAID-induced dyspeptic symptoms. Fifteen Helicobacter pylori-negative, healthy males were administered two types of NSAIDs, a non-selective cyclooxygenase inhibitor, naproxen (300 mg, twice a day), or a cyclooxygenase-2-selective inhibitor, etodolac (200 mg, twice a day), for 1 week in a crossover study, with an interval of ≥ 4 weeks. Study participants underwent endoscopic examinations before and after treatment. Pentagastrin-stimulated gastric secretions were collected for 10 min during endoscopic examinations, and were analyzed for gastric acid levels (mEq/10 min) and mucus output (mg hexose/10 min). The grade of gastric mucosal injury was assessed endoscopically. Among 29 subjects who completed the crossover study, 11 individuals reported abdominal pain following the administration of naproxen or etodolac for 1 week, as judged by elevated pain scores, while 18 individuals did not report abdominal pain. The occurrence of symptoms was not associated with the type of NSAIDs administered or the occurrence of erosive injury visualized by endoscopy. Gastric mucus secretion was significantly increased in subjects without drug-induced abdominal pain (P < 0.05), whereas it was significantly reduced in those with drug-induced abdominal pain (P < 0.05). In conclusion, the occurrence of NSAID-induced abdominal pain is associated with reduced levels of gastric mucus secretion rather than the occurrence of endoscopic mucosal injury.

show abstract

“…This condition can generate bleeding when transforms into erosive gastritis [89], especially in patients with bleeding duodenal or gastric peptic ulcers [90,91] and in patients who chronically consume nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, for the purpose of cardioprotection [92][93][94][95]. Other mechanisms invoked to explain iron deficiency in patients infected with H. pylori are related to changes in gastric physiology, particularly changes in gastric pH and the presence of achlorhydria, which significantly reduces the solubility and intestinal absorption of inorganic iron [40].…”

Section: Pathophysiology Of Iron Deficiency By H Pylorimentioning

confidence: 99%

Helicobacter pylori and Hematologic Diseases

Campuzano-Maya¹

2016

Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview

View full text Add to dashboard Cite

Helicobacter pylori infection is the most common infection of the human species, with developing countries displaying a marked disadvantage in contrast to developing countries. While H. pylori infection is asymptomatic in most infected individuals, it is intimately related to malignant diseases of the stomach, such as gastric cancer and gastric MALT lymphoma, as well as benign diseases, for example chronic gastritis and duodenal and gastric peptic ulcers. Since the discovery that gastric mucosa could be colonized by bacteria, evidence of greater than 50 extragastric manifestations has been reported, linking H. pylori infection and the development of diseases associated with cardiology, dermatology, endocrinology, obstetrics and gynecology, hematology, pneumology, neurology, odontology, ophthalmology, otorhinolaryngology, and pediatrics. This chapter presents the extragastric manifestations of H. pylori infection expressed through hematologic diseases; particularly those included in the international consensus, and discusses guidelines for the management of H. pylori infection, such as iron deficiency, vitamin B 12 (cobalamin) deficiency, and immune thrombocytopenia. Other manifestations reviewed include immune neutropenia, antiphospholipid syndrome, and plasma cell dyscrasias, such us monoclonal gammopathy of undetermined significance, multiple myeloma, and Henoch-Schönlein purpura.

show abstract

The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically‐diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010

Abstract: SUMMARY BackgroundRecent data from Western countries indicate that the aetiology of peptic ulcer disease (PUD) is changing as the prevalence of Helicobacter pylori is decreasing while the use of low-dose aspirin (LDA, 325 mg/day) is increasing.

Cited by 55 publications

References 42 publications

Peptic Ulcer Frequency Differences Related to H. Pylori or Aines

Peptic Ulcer Frequency Differences Related to H. Pylori or Aines

Increased Gastric Mucus Secretion Alleviates Non-Steroidal Anti-Inflammatory Drug-Induced Abdominal Pain

Helicobacter pylori and Hematologic Diseases

Contact Info

Product

Resources

About